Back to the future: the 'old-fashioned' way to new medications for neurodegeneration

[1]  Ann-Shyn Chiang,et al.  Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: A potential model for Alzheimer's disease , 2004 .

[2]  A. Schapira,et al.  Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. , 2004, JAMA.

[3]  D. Selkoe.  Folding proteins in fatal ways , 2003, Nature.

[4]  Fred E. Cohen,et al.  Therapeutic approaches to protein-misfolding diseases , 2003, Nature.

[5]  P. Lansbury,et al.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. , 2003, Annual review of neuroscience.

[6]  Valentina Gelfanova,et al.  Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß42 by Inhibiting Rho , 2003, Science.

[7]  S. Weggen,et al.  The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid β42 Production* , 2003, Journal of Biological Chemistry.

[8]  D. Frail,et al.  A common origin for cosmic explosions inferred from calorimetry of GRB030329 , 2003, Nature.

[9]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Farrer,et al.  Complex interactions in Parkinson's disease: A two‐phased approach , 2003, Movement disorders : official journal of the Movement Disorder Society.

[11]  R. Stein,et al.  A new model for drug discovery--meeting our societal obligation. , 2003, Drug discovery today.

[12]  J. Alper.  Biotech Thinking Comes to Academic Medical Centers , 2003, Science.

[13]  T. Dawson,et al.  Rare genetic mutations shed light on the pathogenesis of Parkinson disease. , 2003, The Journal of clinical investigation.

[14]  M. Cookson.  Pathways to Parkinsonism , 2003, Neuron.

[15]  N. Perrimon,et al.  γ‐Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  E. Shorter.  Looking backwards: a possible new path for drug discovery in psychopharmacology , 2002, Nature Reviews Drug Discovery.

[17]  P. Auluck,et al.  Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.

[18]  P. Lansbury,et al.  Genetics of Parkinson's disease and biochemical studies of implicated gene products. , 2002, Current opinion in genetics & development.

[19]  Biao Chen,et al.  ACT and UCH‐L1 polymorphisms in Parkinson's disease and age of onset , 2002, Movement disorders : official journal of the Movement Disorder Society.

[20]  Peter T Lansbury,et al.  Genetics of Parkinson's disease and biochemical studies of implicated gene products. , 2002, Current opinion in cell biology.

[21]  David H. Hall,et al.  Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Ichiro Kanazawa,et al.  Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms , 2002, Annals of neurology.

[23]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[24]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[25]  M. Wolfe,et al.  A Portrait of Alzheimer Secretases--New Features and Familiar Faces , 2001, Science.

[26]  J. Satoh,et al.  A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population , 2001, Journal of the Neurological Sciences.

[27]  Junying Yuan,et al.  Apoptosis in the nervous system , 2000, Nature.

[28]  E. Mori.  [Dementia with Lewy bodies]. , 2000, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[29]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[30]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[31]  M. Farrer,et al.  Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s disease , 1999, Neurology.

[32]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[33]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[34]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[35]  S. Younkin,et al.  Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. , 1993, Science.

[36]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[37]  P. Mcgeer,et al.  Anti-inflammatory drugs and Alzheimer disease , 1990, The Lancet.

[38]  D. Benson,et al.  Alzheimer's disease and Parkinson's disease , 1988, Neurology.

[39]  Jason E. Schillerstrom,et al.  Diagnostic evaluation of elderly patients with mild memory problems. , 2004, Annals of internal medicine.

[40]  J. Alper.  Drug development. Biotech thinking comes to academic medical centers. , 2003, Science.

[41]  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.